Pure MHC to Partner with AbbVie on Oncology Research
January 09 2017 - 9:00AM
Business Wire
Collaboration will focus on T-cell Receptor
therapeutic targets
Emergent Technologies, Inc. (ETI) announced today that its
target discovery portfolio company, Pure MHC, and global
biopharmaceutical company, AbbVie (NYSE:ABBV), will embark on a
research and license agreement to discover and validate peptide
targets for use with T-cell receptor therapeutics in several types
of cancers.
T-cells play a key role in regulating immune responses to
tumors. Receptors on the surface of T-cells recognize tumor
antigens in the form of small peptides and provide a selective
pathway for targeted cancer therapies. Pure MHC has developed
technology to identify novel, tumor-associated peptides based on
innovation licensed from the University of Oklahoma.
The collaboration between AbbVie and Pure MHC will seek to
identify a library of peptide targets for further research across
multiple tumor types and advance AbbVie’s ongoing development of
next-generation immuno-oncology therapies.
“Our partnership with Pure MHC will advance our research within
immuno-oncology, an important frontier in the ongoing fight against
cancer,” said Steve Davidsen, Ph.D., vice president, oncology
discovery, AbbVie.
“We are excited to partner with AbbVie in the immuno-oncology
space leveraging Pure MHC’s over 15 years of peptide target
discovery with AbbVie’s deep clinical expertise to utilize these
targets in new and improved therapies for the treatment of cancer,”
said Thomas Harlan, Chief Executive Officer at ETI and Pure
MHC.
“We’re tremendously proud of the effort by the Pure MHC team and
Emergent Technologies,” said James Bratton, Assistant Vice
President, Economic Development and Executive Director, Office
of Technology Development at the University of Oklahoma.
"Without their vision, expertise and dedication, none of this would
have been possible. This collaboration with AbbVie demonstrates how
commercialization of university research can have a lasting,
positive impact on the world.”
About Emergent Technologies
Emergent Technologies, Inc. is an innovation solutions and
technology commercialization leader headquartered in Austin, Texas.
For more information visit www.etibio.com.
About Pure MHC
Pure MHC, LLC is a platform technology company funded and
managed by Emergent Technologies, Inc. with expertise in
disease-specific target identification and validation as well as
immunotherapeutic drug development for cancer, infectious and
autoimmune diseases, and allergy. The Pure MHC target discovery
technology was developed by Chief Scientist, William Hildebrand,
PhD. of the University of Oklahoma Health Sciences Center. For more
information, visit www.puremhc.com.
About AbbVie
AbbVie is a global, research-based biopharmaceutical company
formed in 2013 following separation from Abbott Laboratories. The
company's mission is to use its expertise, dedicated people and
unique approach to innovation to develop and market advanced
therapies that address some of the world's most complex and serious
diseases. Together with its wholly-owned subsidiary, Pharmacyclics,
AbbVie employs more than 28,000 people worldwide and markets
medicines in more than 170 countries. For further information on
the company and its people, portfolio and commitments,
visit www.abbvie.com.
About the University of
Oklahoma
Since 1890, the University of Oklahoma (OU) has served the
educational, cultural, economic and health-care needs of the state,
region and nation. OU’s mission is to provide the best
possible educational experience for students through excellence in
teaching, research and creative activity, and service to the state
and society. OU’s Office of Technology Development (OTD) helps OU
researchers transform ideas into tangible impact for the betterment
of society. OTD provides the highest level of fiduciary expertise
for the perfection, conveyance and commercialization of OU
intellectual property, and strives to be recognized as a driving
force for OU's economic impact through education, expertise and
efficiency. For more information, visit otd.ou.edu.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170109005259/en/
Emergent Technologies, Inc.Cameron Mackie,
512-697-8224cmackie@etibio.com
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024